Comparison of the hospital-acquired clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: A systematic review and meta-analysis

Gut and Liver

Volumn 11, Issue 6, 2017, Pages 781-788

  Azab, Mohamed ^a   Doo, Loomee ^a   Doo, Daniel H ^b   Elmofti, Yousif ^a   Ahmed, Muazer ^a   Cadavona, John Jay ^c   Liu, Xibei B ^c   Shafi, Amaan ^c   Joo, Moon Kyung ^d   Yoo, Ji Won ^a  

^a UNIVERSITY OF NEVADA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d Korea University College of Medicine   (South Korea)

Author keywords

Clostridium; Histamine antagonists; Meta analysis; Proton pump inhibitors; Stomach ulcer

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; HISTAMINE AGONIST;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; DATA ANALYSIS; DATA SYNTHESIS; HOSPITAL INFECTION; HUMAN; INFECTION RISK; META ANALYSIS; QUALITY CONTROL; STRESS ULCER; SYSTEMATIC REVIEW; AGED; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTION; COMPLICATION; CROSS INFECTION; FEMALE; MALE; MENTAL STRESS; MICROBIOLOGY; ODDS RATIO; PEPTOCLOSTRIDIUM DIFFICILE; PSYCHOLOGY; RISK FACTOR; STOMACH ULCER; TREATMENT OUTCOME;

AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CROSS INFECTION; FEMALE; HISTAMINE AGONISTS; HUMANS; MALE; ODDS RATIO; PROTON PUMP INHIBITORS; RISK FACTORS; STOMACH ULCER; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 85036646959     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl16568     Document Type: Article

References (40)

1. Bartlett JG, Moon N, Chang TW, Taylor N, Onderdonk AB. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978;75:778-782.
2. Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015;372:825-834.
3. McFarland LV, Mulligan ME, Kwok RY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989;320:204-210.
4. Samore MH, Venkataraman L, DeGirolami PC, Arbeit RD, Karchmer AW. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med 1996;100:32-40.
5. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93:175-181.
6. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-280.
7. Kazakova SV, Ware K, Baughman B, et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166:2518-2524.
8. Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA. Clostridium difficile infection in an urban medical center: five-year analysis of infection rates among adult admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci 2007;37:241-247.
9. Dubberke ER, Reske KA, Olsen MA, et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. Arch Intern Med 2007;167:1092-1097.
10. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-2313.
11. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010;170:784-790.
12. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-1703.
13. Stevens V, Dumyati G, Brown J, Wijngaarden E. Differential risk of Clostridium difficile infection with proton pump inhibitor use by level of antibiotic exposure. Pharmacoepidemiol Drug Saf 2011;20:1035-1042.
14. Barletta JF, El-Ibiary SY, Davis LE, Nguyen B, Raney CR. Proton pump inhibitors and the risk for hospital-acquired Clostridium difficile infection. Mayo Clin Proc 2013;88:1085-1090.
15. Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care 2014;18:714.
16. Ro Y, Eun CS, Kim HS, et al. Risk of Clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically Ill patients. Gut Liver 2016;10:581-586.
17. Thorens J, Froehlich F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39:54-59.
18. U.S. Food & Drug Administration. Drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs) [Internet]. Silver Spring: FDA; c2016 [cited 2016 Nov 10]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.
19. Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS One 2012;7:e50836.
20. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-1019.
21. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001-1010.
22. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012;10:225-233.
23. MacLaren R, Reynolds PM, Allen RR. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit. JAMA Intern Med 2014;174:564-574.
24. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-269.
25. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-926.
26. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence: imprecision. J Clin Epidemiol 2011;64:1283-1293.
27. GRADEpro [Internet]. Hamilton: McMaster University; 2015 [cited 2016 Nov 10]. Available from: http://www.guidelinedevelopment.org.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
29. ASHP therapeutic guidelines on stress ulcer prophylaxis: ASHP Commission on Therapeutics and approved by the ASHP board of directors on November 14, 1998. Am J Health Syst Pharm 1999;56:347-379.
30. Guillamondegui OD, Gunter OL, Bonadies JA, et al. Practice management guidelines for stress ulcer prophylaxis: EAST Practice Management Guidelines Committee [Internet]. Chicago: Eastern Association for the Surgery of Trauma; c2008 [cited 2016 Nov 10]. Available from: http://www.east.org/education/practice-management-guidelines/stress-ulcer-prophylaxis.
31. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001;5:368-375.
32. Grube RR, May DB. Stress ulcer prophylaxis in hospitalized patients not in intensive care units. Am J Health Syst Pharm 2007;64:1396-1400.
33. Choudhry MN, Soran H, Ziglam HM. Overuse and inappropriate prescribing of proton pump inhibitors in patients with Clostridium difficile-associated disease. QJM 2008;101:445-448.
34. Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P, Cook DJ. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 2013;41:693-705.
35. Barkun AN, Adam V, Martel M, Bardou M. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists. Value Health 2013;16:14-22.
36. Harris RA, Kuppermann M, Richter JE. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. Am J Gastroenterol 1997;92:2179-2187.
37. Dubberke ER, Olsen MA. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 2012;55 Suppl 2:S88-S92.
38. Olsen MA, Young-Xu Y, Stwalley D, et al. The burden of Clostridium difficile infection: estimates of the incidence of CDI from U.S. administrative databases. BMC Infect Dis 2016;16:177.
39. Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005;6:105-108.
40. Dubberke ER, Olsen MA, Stwalley D, et al. Identification of medicare recipients at highest risk for Clostridium difficile infection in the US by population attributable risk analysis. PLoS One 2016;11:e0146822.